NOW APPROVED
for the treatment of patients with classical Hodgkin
lymphoma (HL) at high risk of relapse or progression
as post-auto-HSCT consolidation.1
VISIT ADCETRIS.com to:
Get full Prescribing Information
Download a patient brochure
Request a visit from a Seattle Genetics representative
medications may also increase the risk. Monitor liver
enzymes and bilirubin. Patients experiencing new,
worsening, or recurrent hepatotoxicity may require a
delay, change in dose, or discontinuation of ADCETRIS.
• Progressive multifocal leukoencephalopathy (PML):
JC virus infection resulting in PML and death has been
reported in ADCETRIS-treated patients. First onset of
symptoms occurred at various times from initiation of
ADCETRIS therapy, with some cases occurring within
3 months of initial exposure. In addition to ADCETRIS
therapy, other possible contributory factors include
prior therapies and underlying disease that may cause
immunosuppression. Consider the diagnosis of PML in
any patient presenting with new-onset signs and
symptoms of central nervous system abnormalities.
Hold ADCETRIS if PML is suspected and discontinue
ADCETRIS if PML is confirmed.
• Pulmonary toxicity: Events of noninfectious pulmonary
toxicity including pneumonitis, interstitial lung disease,
and acute respiratory distress syndrome, some with fatal
outcomes, have been reported. Monitor patients for signs
and symptoms of pulmonary toxicity, including cough and
dyspnea. In the event of new or worsening pulmonary
symptoms, hold ADCETRIS dosing during evaluation and
until symptomatic improvement.
• Serious dermatologic reactions: Stevens-Johnson
syndrome (SJS) and